Sellas Life's reported Net Income and the formula behind it are documented below with the most recent data. The reported value follows from applying the standard formula to filed data. Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Net Income
=
(Rev + Gain)
-
(Exp + Loss)
=
-26.86 M
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales. This Net Income figure for Sellas Life is based on recent reported data. The dataset reflects available financial reporting inputs.
Changes in Net Loss often reflect shifts in Sellas Life's operating environment or capital decisions.
Latest Sellas Life's Net Loss Growth Pattern
Sellas Life Sciences's Net Loss over the past 15 years is plotted below. A very volatile pattern across the series may reflect cyclical or seasonal influences. The interplay between trend direction and volatility shapes the risk profile of this metric. The annual reporting cadence smooths out intra-year noise, revealing the underlying direction. Peaks and troughs in Sellas Life's Net Loss highlight where the most significant shifts occurred.
Effective analysis of Sellas Life starts with recognizing how Net Income and Sellas Life's other accounts are interdependent. Understanding these correlations allows investors to focus on the most significant financial relationships at Sellas Life. For Sellas Life, the relationship between Net Income and other accounts often signals shifts in fundamental trajectory. Understanding these account-level relationships is a key step toward projecting Sellas Life's future financial trajectory.
In the latest reporting cycle, Accumulated Other Comprehensive Income is on a downward trend. The prior-year reading for Accumulated Other Comprehensive Income was 0.00.
Based on the recorded statements, Sellas Life Sciences reported net income of -26.86 Million. The Biotechnology sector average is 107.87% above this level, and the Health Care industry average is 138.35% above. Sellas Life is also 104.7% lower than the broader all United States stocks average.
Fundamental Drivers Relationships
Peer multiple analysis evaluates Sellas Life's pricing efficiency within its industry. Cross-referencing Sellas Life's key ratios against peer benchmarks through ratio comparison sharpens the view on relative valuation and competitive positioning. More Info.
Sellas Life Sciences maintains a fifth standing in net income relative to competitors. It is rated below average in return on asset relative to competitors . Sellas Life’s Net Loss is trending toward -28.21 Million, a 4.76% year-over-year shift. In the prior fiscal year, Net Loss was reported at -26.86 Million. Earnings multiples remain central to Sellas Life's valuation analysis.
Net Income Peer Comparison
Peer comparison of Sellas Life using Net Income provides a quantitative benchmark against similar stocks. Identifying gaps in Sellas Life's Net Income relative to peers supports more targeted investment analysis. This relative framework helps distinguish company-specific Net Income drivers from broader sector trends. Investors benefit from reviewing Sellas Life's Net Income peer data as part of a broader comparative analysis.
Sellas Life is currently under evaluation in net income relative to competitors.
Institutional Holders
Large financial institutions and pension funds that own Sellas Life collectively form its institutional holder base. Institutional investors often accumulate meaningful positions and use their influence to engage with Sellas Life's management. The concentration of institutional ownership in Sellas Life affects both stock liquidity and price stability. Consider Sellas Life's institutional ownership alongside other governance and fundamental indicators.
An assessment of Sellas Life's core fundamentals focuses on profitability drivers and balance-sheet composition. Cost discipline impacts margin consistency over time. For this reporting period, Sellas Life reflects EPS loss of 0.28, current ratio of 2.36, debt-to-equity of 0.06.
Unless otherwise specified, data for Sellas Life Sciences is compiled from periodic company reporting and market reference feeds and standardized for comparability. Professional analyst research is incorporated when coverage is available. Updates may occur throughout the day. Accounting-line values follow GAAP or IFRS structures as published in issuer filings.